Skip to main content
. 2021 Mar 3;12(2):395–425. doi: 10.1016/j.jcmgh.2021.02.013

Figure 9.

Figure 9

Rev-erbα has no effects on blood, spleen, or BM CD45+CD11c–Ly6G–CD11b+CD68–myeloid cells during H pylori infection. (A) Representative dot plots of CD45+CD11c–Ly6G–CD11b+CD68– myeloid cells by gating on CD45+ cells in peripheral blood, spleen or BM of WT H pylori–infected WT mice 8 weeks p.i.. (B–D) The levels of CD45+CD11c–Ly6G–CD11b+CD68– myeloid cells in (B) peripheral blood, spleen, or BM of WT H pylori–infected WT and Rev-erbα–/– mice; (C) gastric mucosa of WT H pylori–infected mice injected with Rev-erbα agonist SR9009 or cremophor control, or Rev-erbα antagonist SR8278 or DMSO control; or (D) gastric mucosa of WT H pylori–infected BM chimera mice were compared 8 weeks p.i. (n = 5). n.s. P > .05 for groups connected by horizontal lines.